Hemophilia Drugs Market 2019 Analysis, Exhibit 6.0% CAGR and Remarkable Growth Rate forecast till 2025

Hemophilia Drugs Market is projected for better diagnosis because patients with hemophilia suffer from an abnormal blood loss and this weakens their blood clotting process, Hemophilia Drugs Industry exhibit a 6.0% & strong growth in the coming years

pune, india - May 16, 2019 /MarketersMedia/ —

The Global Hemophilia Drugs Market covered a value of US$ 9875.4 Mn in the year 2017 and is anticipated to reach US$ 15830.3 Mn by 2025. Furthermore, the global market for hemodialysis is expected to report a CAGR of 6.0% during the forecast period. The above information was published in a report, titled “Hemophilia Drugs Market Size, Share and Global Trend by Disease Indication (Hemophilia A, B & C), Therapy Type (Recombinant Therapy, Plasma therapy & Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2025.”

The rising prevalence of severe diseases is one of the major concerns in the healthcare industry. Among these disorders, patients with hemophilia suffer from an abnormal blood loss and this weakens their blood clotting process. Companies are introducing novel hemophilia drugs and therapies to fulfil the unmet needs of patients and maintain their quality of life. A lead analyst at Fortune Business Insights said, “Companies are building expansion strategies to develop new hemophilia drugs so as to offer better diagnosis.”

Among disease indications, hemophilia A is projected to exhibit a strong growth in the coming years. In addition to this, this segment covered a share of 85% in the global hemophilia drugs market in 2017. This is mainly attributable to the rising pool patients suffering from hemophilia across the world. Also, rising initiatives at developing and commercializing new products for the effective treatment of hemophilia is driving this segment’s growth. Following hemophilia A, hemophilia B drugs are also expected to grow at a considerable rate in the years to come.

Request Sample Copy at https://www.fortunebusinessinsights.com/enquiry/sample/hemophilia-drugs-market-100068

Asia Pacific to Grow at a Rapid Pace with Rising Number of Hemophilia Patients

North America is projected to emerge dominant in the global hemophilia drugs market during the forecast period. This is mainly ascribable to the rising prevalence of hemophilia A and B, especially in countries such as Canada and the U.S. Moreover, in 2017, North America market for hemophilia drugs covered a value of US$ 3,684.7 Mn. Trailing North America, Europe is the second-leading region in the global hemophilia drugs market. The growth in this region is attributable to the rising healthcare budgets by governments and initiatives by governments to promote hemophilia drugs treatment. On the other hand, the hemophilia drugs market in Asia Pacific is likely to expand at a higher CAGR between 2017 and 2025 on account of rising number of patients suffering from hemophilia especially in countries such as China and India.

Rising Awareness About Hemophilia to Augment the Demand

The primary factor augmenting the hemophilia drugs market is the recent developments in hemophilia treatment. A lead analyst at Fortune Business Insights said “Several new drugs are expected to enter the global market in the coming years.” Also, hemophilia surgical management is gaining traction on account of increasing awareness about hemophilia across the world. Moreover, governments are planning to conduct awareness initiatives to spread knowledge regarding the use of hemophilia treatment and drugs This, in turn, is expected to drive the hemophilia drugs market over the next few years. The genetic evolution is leading to rising incidences of bleeding disorders across the world. This will further lead to hemophilia drug development in the next few years to come. As per the study conducted by the National Hemophilia Foundation or NHF in 2015, about 1% of the U.S. population is likely to suffer from a disease called von Willebrand, hence rising the need for hemophilia treatment drugs.

Pfizer Introduced Gene Therapy to Address Unmet Patient’s Needs

Some of the leading players presently operating in the global market for hemophilia drugs are Grifols SA, Bioverativ Inc., FERRING LÄKEMEDEL AB, Aptevo Therapeutics, Hoffmann-La Roche Ltd, Novo Nordisk, Pfizer, Inc. and CSL Behring. In 2018, companies such as Novo Nordisk, Takeda Pharmaceutical Company Ltd., and F. Hoffmann-La Roche Ltd covered more than half of the share in the global hemodialysis market as per revenue. In 2017, Pfizer, Inc. collaborated with Sangamo Therapeutics, Inc. to commercialize and develop gene therapy programs. The aim was to utilize these programs for Hemophilia A drugs.

Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/hemophilia-drugs-market-100068

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Info:
Name: Fortune Business Insights
Email: Send Email
Organization: Fortune Business Insights
Address: Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India
Phone: 1 424 253 0390
Website: https://www.fortunebusinessinsights.com

Source URL: https://marketersmedia.com/hemophilia-drugs-market-2019-analysis-exhibit-60-cagr-and-remarkable-growth-rate-forecast-till-2025/513243

Source: MarketersMedia

Release ID: 513243

More News From The World Agenda

CEO Pay: When investors say "nay" on spiraling packages

May 25, 2019

NEW YORK — Shareholders are still voting overwhelmingly in favor of big pay packages for CEOs, but there are more pockets of resistance eight years after "Say on Pay" became a mandatory exercise at annual meetings. Median pay for CEOs at the biggest U.S. companies climbed 7% to $12 million last year, according to data analyzed by Equilar for The Associated Press. The median increase for a typical worker at these companies was 3%. Median means half were larger, and half were smaller. The stock market is in the midst of the longest bull run on record. Earnings per share...

Missouri governor signs bill banning abortions at 8 weeks

May 25, 2019

JEFFERSON CITY, Mo. — Missouri Gov. Mike Parson on Friday signed a bill that bans abortions on or beyond the eighth week of pregnancy without exceptions for cases of rape or incest, making it among the most restrictive abortion policies in the nation. Under the law that comes into force Aug. 28, doctors who violate the eight-week cutoff could face five to 15 years in prison. Women who terminate their pregnancies cannot be prosecuted. A legal challenge is expected, although it's unclear when that might occur. The measure includes exceptions for medical emergencies, such as when there is a risk...

US orders for long-lasting goods fall 2.1% in April

May 25, 2019

WASHINGTON — Orders to U.S. factories for large manufactured goods fell sharply last month, pulled down by lower demand for commercial aircraft and cars, while businesses also pulled back on investment spending. The Commerce Department said Friday that orders for durable goods — or items meant to last at least three years — fell 2.1%, after rising 1.7% in March, which was revised lower from a previous estimate of a 2.6% gain. Orders also fell steeply in February. The report prompted numerous economists to take a more bearish view of the economy in the April-June quarter. Michael Feroli, an economist...

CEOs get $800,000 pay raise, leaving workers further behind

May 25, 2019

NEW YORK — Did you get a 7% raise last year? Congratulations, yours was in line with what CEOs at the biggest companies got. But for chief executives, that 7% was roughly $800,000. Pay for CEOs at S&P 500 companies rose to a median of $12 million last year, including salary, stock and other compensation, according to data analyzed by Equilar for The Associated Press. The eight-figure packages continue to rise as companies tie more of their CEOs' pay to their stock prices, which are still near record levels, and as profits hit an all-time high last year due to...

HHS rolls back protections for transgender people

May 25, 2019

WASHINGTON — A new Trump administration rule would roll back sex discrimination protection for transgender people in health services. In the proposed rule issued Friday, the Health and Human Services Department says laws banning sex discrimination in health care don't apply to people's "gender identity." LGBT groups have long warned such a move could lead to denial of needed medical care. That rule reverses the policy of the Obama administration, which had found that sex discrimination laws do protect transgender people. It faces a 60-day comment period and court challenges are expected. Under the Obama-era rule, a hospital could be...

Here at The World Agenda, we bring innovation to digital news for you to keep abreast of worldwide news instantly anywhere.

Contact us: sales[at]theworldagenda.com